EUCTR2012-000437-39-ES进行中（未招募）不适用
ARTFORCE - Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE.A randomised study with Cisplatinum or Cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer - ARTFORCE
Stichting Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 268 人开始时间: 2012年3月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 268
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Stage III-IV, T3-4, SCC Head and Neck, <70 years, GFR >60, Performance status: WHO 0-1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 68
排除标准
- •Inability to receive one of the treatment arms, laryngeal cancer, known active symptomatic infections, prior surgery, radiotherapy or chemotherapy for this tumor
研究者
相似试验
尚未招募
不适用
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal carcinomarectal cancer100179901001799110017998NL-OMON51912niversitair Medisch Centrum Utrecht45
招募中
不适用
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal cancerNL-OMON22916MC Utrecht45
尚未招募
Unknown
Radiationtreatment planning for Cervical and Head andNeck cancer using machineCTRI/2023/05/053119Medical Research Council University College London
招募中
不适用
RADprecise - Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicityC50C61Malignant neoplasm of breastMalignant neoplasm of prostateDRKS00020290Deutsches Krebsforschungszentrum (DKFZ) / German Cancer Research Center1,050
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy for patients with localregional relapse in breast cancer scheduled to be treated with radiotherapy, hyperthermia and Lyso-Thermosenstive Liposomal DoxorubiciEUCTR2015-000167-14-ITCELSION CORPORATIO70